Human FCAR/CD89 Alexa Fluor® 405-conjugated Antibody Summary
Accession # P24071
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
FCAR, also called Fc alpha RI or CD89, is a variably glycosylated 50‑100 kDa myeloid-specific type I transmembrane (TM) Fc receptor for IgA that is a member of the multichain immune recognition receptor (MIRR) family (1‑3). Human FCAR contains a 21 amino acid (aa) signal sequence and extracellular (ECD), TM and cytoplasmic domains of 206, 19 and 41 aa, respectively (4). Arg230 within the TM domain supports interaction with the ITAM-containing signaling subunit, FcR gamma, which contains a TM Asp (5‑7). Two ECD C2-type Ig-like domains (EC1 and 2) are oriented at right angles (8). Up to two molecules of FCAR can bind one molecule of serum IgA via EC1 (8). Many splice variants have been reported, but only two have been identified as proteins (9, 10). The a.2 form, which lacks 22 aa just prior to the TM domain, is exclusively expressed in alveolar macrophages. The a.3 form lacks EC2. FCAR binds monomeric, polymeric and secretory IgA, but does not mediate the barrier function of secretory IgA in mucosal epithelium (1‑3). Shedding and circulation of polymeric IgA/FCAR immune complexes has been reported (11). Circulating neutrophils, eosinophils, and monocytes express FCAR (12). Tissue expression of FCAR is mainly from neutrophils; FCAR is downregulated as monocytes differentiate to tissue macrophages (12). On neutrophils, a significant amount of FCAR lacks FcR gamma, but can still be endocytosed to early endosomes and recycled to the cell surface (5). Binding of serum IgA to FCAR is transient and anti-inflammatory, inhibiting IgG or IgE-induced degranulation (6). Sustained aggregation of FCAR results in inflammatory responses (6). FcR gamma signaling is required for these and for transport to late endosomes (5‑7). Human FCAR shows 55‑58% aa identity with rat, horse and cow FCAR. No ortholog occurs in mouse. FCAR structure resembles the KIR/ILT/LIR/MIR family more than other IgA receptors, including pIgR, Fc alpha /μR, asialoglycoprotein receptor (ASGR1) and transferrin receptor (TfR) (1‑3).
- Wines, B. D. and P. M. Hogarth (2006) Tissue Antigens 68:103.
- Otten, M. A. and M. van Egmon (2004) Immunol. Lett. 92:23.
- Montiero, R. C. and J. G. J. van de Winkel (2003) Annu. Rev. Immunol. 21:177.
- Maliszewski, C. R. et al. (1990) J. Exp. Med. 172:1665.
- Launay, P. et al. (1999) J. Biol. Chem. 274:7216.
- Pasquier, B. et al. (2005) Immunity 22:31.
- Shen, L. et al. (2001) Blood 97:205.
- Herr, Y. et al. (2003) Nature 423:614.
- Patry, C. et al. (1996) J. Immunol. 156:4442.
- Togo, S. et al. (2003) FEBS Lett. 535:205.
- van der Boog, P. J. M. et al. (2002) J. Immunol. 168:1252.
- Hamre, R. et al. (2003) Scand. J. Immunol. 57:506.
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human FCAR/CD89 Alexa Fluor® 405-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human FCAR/CD89 Alexa Fluor® 405-conjugated Antibody and earn rewards!
Have you used Human FCAR/CD89 Alexa Fluor® 405-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image